company background image
A149300 logo

Apures XKON:A149300 Stock Report

Last Price

₩318.00

Market Cap

₩8.8b

7D

3.6%

1Y

-30.7%

Updated

19 Jan, 2025

Data

Company Financials

A149300 Stock Overview

Engages in the development and commercialization of solutions for the bio and medical industries in South Korea. More details

A149300 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Apures Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Apures
Historical stock prices
Current Share Price₩318.00
52 Week High₩517.00
52 Week Low₩266.00
Beta0
1 Month Change-1.85%
3 Month Change-3.34%
1 Year Change-30.72%
3 Year Change-87.10%
5 Year Change-83.22%
Change since IPO-87.53%

Recent News & Updates

Recent updates

Shareholder Returns

A149300KR BiotechsKR Market
7D3.6%-2.7%0.3%
1Y-30.7%24.8%-1.5%

Return vs Industry: A149300 underperformed the KR Biotechs industry which returned 24.8% over the past year.

Return vs Market: A149300 underperformed the KR Market which returned -1.5% over the past year.

Price Volatility

Is A149300's price volatile compared to industry and market?
A149300 volatility
A149300 Average Weekly Movement10.8%
Biotechs Industry Average Movement8.9%
Market Average Movement6.7%
10% most volatile stocks in KR Market12.8%
10% least volatile stocks in KR Market3.4%

Stable Share Price: A149300's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A149300's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
2001n/aChoi Sundeokwww.apures.com

Apures Co., Ltd. engages in the development and commercialization of solutions for the bio and medical industries in South Korea. It is involved in the development of MICROPIG, which are research and laboratory mini pig species to provide solutions through standardization of biomaterials for medical experiments and development of regenerative medicine treatments, including cell therapy and heterogeneous organs. The company provides Porcine Primary Cell for in vitro test; and heterogeneous organ technology, a technology that develops and transplants animal tissues and organs to replace human tissues and organs.

Apures Co., Ltd. Fundamentals Summary

How do Apures's earnings and revenue compare to its market cap?
A149300 fundamental statistics
Market cap₩8.82b
Earnings (TTM)₩0
Revenue (TTM)n/a

n/a

P/E Ratio

n/a

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A149300 income statement (TTM)
Revenue₩0
Cost of Revenue₩0
Gross Profit₩0
Other Expenses₩0
Earnings₩0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did A149300 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/19 01:54
End of Day Share Price 2025/01/17 00:00
EarningsN/A
Annual EarningsN/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Apures Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution